RS20050796A - Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent - Google Patents

Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Info

Publication number
RS20050796A
RS20050796A YUP-2005/0796A YUP79605A RS20050796A RS 20050796 A RS20050796 A RS 20050796A YU P79605 A YUP79605 A YU P79605A RS 20050796 A RS20050796 A RS 20050796A
Authority
RS
Serbia
Prior art keywords
release form
agent
prokinetic agent
pharmaceutically acceptable
gastric acid
Prior art date
Application number
YUP-2005/0796A
Other languages
English (en)
Inventor
Rajesh JAIN
Kour Chand Jindal
Sukhjeet Singh
Original Assignee
Panacea Biotec Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd., filed Critical Panacea Biotec Ltd.,
Publication of RS20050796A publication Critical patent/RS20050796A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Obezbeđene su oralne farmaceutske smeše i postupak za njihovo dobijanje, koje sadrže najmanje jedno sredstvo za suzbijanje želudačne kiseline, pogodno inhibitor protonske pumpe ili njegovu farmaceutski prihvatljivu so, ester, hidrate, derivate ili prolekove, opciono sa farmaceutski prihvatljivim inertnim puniocima, okarakterisane time što je sredstvo za suzbijanje želudačne kiseline prisutno u obliku sa odloženim otpuštanjem, a prokinetičko sredstvo je prisutno u bimodalnom obliku otpuštanja kao što su oblik sa trenutnim otpuštanjem koji ozbebeđuje početnu količinu doze, i oblik sa odloženim otpuštanjem koji obezbeđuje dozu sa vremenskom zadrškom; pod uslovom da prokinetičko sredstvo nije formulisano korišćenjem polimera koji kontroliše stepen hidrofilnosti i nije prisutno u obliku sa podržanim otpuštanjem. Takođe je obezbeđen metod za tretiranje oboljenja gastro ezofagalnog refluksa, refluksnog ezofagitisa, peptičkog ulkusa, želudačnog ulkusa, i drugih poremećaja vezanih za želudačnu kiselinu, davanjem pacijentu farmaceutske smeše prema potrebi.
YUP-2005/0796A 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent RS20050796A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN25DE2004 2004-01-06
IN21DE2004 2004-01-06
PCT/IN2005/000002 WO2005065664A1 (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Publications (1)

Publication Number Publication Date
RS20050796A true RS20050796A (en) 2007-08-03

Family

ID=34751863

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0796A RS20050796A (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Country Status (11)

Country Link
US (1) US20070160664A1 (sr)
EP (1) EP1729743A1 (sr)
AP (1) AP2006003703A0 (sr)
AU (1) AU2005204014B2 (sr)
BR (1) BRPI0506704A (sr)
CA (1) CA2552627A1 (sr)
EA (1) EA012261B1 (sr)
NZ (1) NZ548780A (sr)
RS (1) RS20050796A (sr)
WO (1) WO2005065664A1 (sr)
ZA (1) ZA200606409B (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
RU2467747C2 (ru) * 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
AU2008241532A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
EP2563341A1 (en) * 2010-04-26 2013-03-06 Mahmut Bilgic Pharmaceutical compositions inducing synergistic effect
EP2601936A4 (en) * 2010-08-03 2014-03-19 Eisai R&D Man Co Ltd COMPRESSED COMPOSITION
BRPI1103093A2 (pt) * 2011-06-03 2013-07-02 Eurofarma Laboratarios Ltda composiÇço farmacÊutica oral e uso da composiÇço farmacÊutica oral
KR20130024644A (ko) * 2011-08-31 2013-03-08 한국유나이티드제약 주식회사 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법
RU2697836C2 (ru) * 2015-06-26 2019-08-21 Кореа Юнайтед Фарм. Инк. Комбинированный препарат мозаприда и рабепразола
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001803A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
JP2001507359A (ja) * 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー 徐放性シサプリドミニ錠剤製剤
US6521255B2 (en) * 2000-01-13 2003-02-18 Osmotica Corp. Osmotic device containing ranitidine and a prokinetic agent
EP1596838A2 (en) * 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Also Published As

Publication number Publication date
NZ548780A (en) 2008-09-26
WO2005065664A8 (en) 2005-10-20
ZA200606409B (en) 2008-06-25
WO2005065664A1 (en) 2005-07-21
BRPI0506704A (pt) 2007-05-02
AP2006003703A0 (en) 2006-08-31
EA200601286A1 (ru) 2007-02-27
CA2552627A1 (en) 2005-07-21
AU2005204014B2 (en) 2008-02-28
AU2005204014A1 (en) 2005-07-21
EA012261B1 (ru) 2009-08-28
US20070160664A1 (en) 2007-07-12
EP1729743A1 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
RU2013121788A (ru) Ингибиторы репликации вич
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MX2010001071A (es) Formas de dosificacion retentivas gastricas pulsatiles.
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
JP2006518751A5 (sr)
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
AR075148A1 (es) Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina
TW200624126A (en) New modified release tablet formulations for proton pump inhibitors
RS20050796A (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
WO2008023258A8 (en) Piperidine derivatives
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
WO2008009210A8 (fr) Composés de dihydropyrimidine optiquement purs et leurs utilisations dans la fabrication d'un médicament pour traiter ou prévenir des viroses
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
WO2008002567A3 (en) Methods of treating conditions by sustained release administration of benzimidazole derivatives
CA2633077A1 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MX2013001637A (es) Composiciones farmaceuticas de liberacion controlada oral de blonanserina.
AU2007278986B2 (en) Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
WO2010038241A3 (en) Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
MX2012007927A (es) Antagonistas de dp2 y usos del mismo.
CA2648538A1 (en) Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles